Quintet Private Bank Europe S.A. Grows Stock Holdings in BioNTech SE (NASDAQ:BNTX)

Quintet Private Bank Europe S.A. grew its holdings in BioNTech SE (NASDAQ:BNTX) by 823.5% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 785 shares of the company’s stock after purchasing an additional 700 shares during the quarter. Quintet Private Bank Europe S.A.’s holdings in BioNTech were worth $88,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of the business. Jones Financial Companies Lllp increased its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock valued at $53,000 after purchasing an additional 246 shares during the last quarter. Planning Capital Management Corp increased its holdings in BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. GAMMA Investing LLC increased its holdings in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after purchasing an additional 300 shares during the last quarter. AlphaCentric Advisors LLC acquired a new stake in BioNTech in the 4th quarter valued at approximately $168,000. Finally, SVB Wealth LLC acquired a new stake in BioNTech in the 4th quarter valued at approximately $204,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on BNTX shares. BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research note on Monday, December 2nd. TD Cowen dropped their price target on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research note on Tuesday, November 5th. JPMorgan Chase & Co. dropped their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. Canaccord Genuity Group boosted their price target on shares of BioNTech from $171.00 to $171.44 and gave the stock a “buy” rating in a research note on Wednesday, November 27th. Finally, Wells Fargo & Company started coverage on shares of BioNTech in a research note on Wednesday, December 11th. They issued an “overweight” rating and a $170.00 price target for the company. Three analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, BioNTech currently has an average rating of “Moderate Buy” and an average price target of $142.72.

BioNTech Price Performance

Shares of BNTX stock opened at $111.56 on Tuesday. The firm has a market cap of $26.75 billion, a P/E ratio of -53.12 and a beta of 0.17. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. BioNTech SE has a 1-year low of $76.53 and a 1-year high of $131.49. The firm has a fifty day moving average of $117.14 and a two-hundred day moving average of $112.28.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.